logo-loader
viewZynerba Pharmaceuticals

Zynerba to present Fragile X CONNECT-FX study data at virtual child neurology events

The study describes the role of what’s called FMR1 methylation in patients with Fragile X syndrome as it correlates to disease severity and as a prognostic biomarker

Brain graphic
CONNECT-FX was a randomized, double-blind, multinational, 14-week pivotal study to evaluate the efficacy and safety of Zygel in children/adolescents aged 3 to 17 years

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), a developer of transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster describing its recent study of CBD in pediatric patients with Fragile X syndrome. 

The study is known as CONNECT-FX, or Clinical study Of CaNNabidiol in ChildrEn and AdolesCenTs with Fragile X. It describes the role of what’s called FMR1 methylation in patients with Fragile X syndrome (FXS) as it correlates to disease severity and as a prognostic biomarker. 

The data will presented at the virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting. The company will also give an oral presentation during the “Research Pipeline: New Findings on Diagnostic and Therapeutics” session of the virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting on October 23.

READ: Zynerba says two poster presentations about its CBD gel were accepted for a virtual child neurology conference

A copy of the poster titled, “ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents With Fragile X Syndrome: Role of Methylation Status as a Correlate to Disease Severity and as a Prognostic Biomarker” is available at http://zynerba.com/publications/.

“We are excited to provide an update on the potential role of methylation status of the FMR1 gene as a predictive biomarker of preferential response to Zygel (ZYN002) in the treatment of the behavioral symptoms of FXS,” Chief Medical Officer Joseph Palumbo said in a statement. “These new data demonstrate that in patients diagnosed with FXS with a fully methylated FMR1 gene significantly more patients who received Zygel achieved a clinically meaningful improvement in their behavioral symptoms compared to patients who received placebo.”

Recent studies have suggested that neuropsychiatric conditions like Fragile X Syndrome — the most common form of inherited learning disability and attention deficit disorder — are associated with a disruption in the endocannabinoid system, and CBD may improve certain core social and behavioral symptoms by modulating the biological system.

CONNECT-FX was a randomized, double-blind, multinational, 14-week pivotal study to evaluate the efficacy and safety of Zygel in children/adolescents aged 3 to 17 years. 

In a previous statement, Zynerba said Zygel did not achieve statistical significance versus placebo in the primary endpoint of improvement in the Social Avoidance subscale of the Aberrant Behavior Checklist – Community FXS (ABC-CFXS).

However, the company said a pre-planned ad hoc analysis of the most severely impacted patients in the trial —  patients having at least 90% methylation (full methylation) of the impacted FMR1 gene — demonstrated that patients receiving Zygel achieved statistical significance in the primary endpoint of improvement at 12 weeks of treatment in the Social Avoidance subscale of the ABC-CFXS compared to placebo.

Zynerba said it determined that 58.2% of FMet patients receiving Zygel achieved a clinically meaningful change in their socially avoidant behavior compared to 40.6% of patients receiving placebo, and 40.3% of patients receiving Zygel achieved a clinically meaningful change in Irritability compared to 23.8% of patients receiving placebo.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Zynerba Pharmaceuticals

Price: 3.72 USD

NASDAQ:ZYNE
Market: NASDAQ
Market Cap: $108.83 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Zynerba Pharmaceuticals well-funded for its CBD clinical trials into 2021

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) CEO Armando Anido tells Proactive Investors the Pennsylvania-based biotech has $59.8 million to fund clinical trials for its cannabis-derived treatments 'beyond major milestones' into 2021. Zynerba is on track to report top-line results from tests...

on 12/3/19

3 min read